Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting metabolic and endocrine disorders. The company’s research and development efforts center on small-molecule agonists and mimetics designed to modulate hormone receptors and growth factors. Its lead programs include VK2809, a selective thyroid hormone receptor beta agonist in development for non-alcoholic steatohepatitis (NASH) and dyslipidemia, and VK5211, a keratinocyte growth factor-1 (KGF-1) mimetic for the treatment of muscle wasting and sarcopenia.
In addition to its most advanced candidates, Viking’s pipeline features VK0214, a thyroid hormone receptor beta agonist being explored for X-linked adrenoleukodystrophy, and earlier-stage programs aimed at addressing obesity and other metabolic diseases. The company leverages preclinical models and Phase 1/2 clinical studies to optimize dosing, safety, and efficacy profiles, seeking to advance multiple candidates toward pivotal trials over the coming years.
Founded in 2014 and headquartered in San Diego, California, Viking Therapeutics operates research collaborations and clinical trial sites across the United States and Europe. The company’s infrastructure supports medicinal chemistry, pharmacology, and biomarker research aimed at accelerating the translation of its small-molecule assets from laboratory to clinic.
Under the leadership of Chief Executive Officer Brian Lian, Viking Therapeutics has assembled a management team with extensive experience in endocrinology and metabolic drug development. The company’s strategic focus on hormone receptor modulation positions it to address significant unmet needs in chronic liver disease, muscle wasting, and lipid disorders.
